CT evaluation of patent artery after percutaneous cryoablation of renal cell carcinoma

Purpose: The purpose of this retrospective study was to determine the incidence of persistent patent artery after percutaneous cryoablation of renal cell carcinoma (RCC) and the relationship between patent arteries one month after cryoablation and early tumor progression. Materials and methods: One hundred and fifty-nine patients (112 men, 47 women; mean age, 63.6 ± 14.6 [SD] years; age range: 21–91 years) who underwent percutaneous cryoablation for 186 RCCs (mean diameter, 1.9 ± 0.6 [SD] cm; range: 0.7–4.0 cm) were retrospectively included. After cryoablation, patients underwent contrast-enhanced computed tomography (CT) with ≤ 2-mm slice thickness within one week from cryoablation, and at one, three, and six months. The time course of patent artery in the ablated renal parenchyma after cryoablation was the primary endpoint. The relationships between patent arteries one month after cryoablation and treatment effectiveness, tumor vascularity, tumor enhancement one month after cryoablation, tumor subtype, and renal function changes were evaluated as secondary endpoints. Results: CT showed patent arteries in the ablated renal parenchyma within one week in 166 RCCs (89.2%), at one month in 54 RCCs (29.0%), at three months in 8 RCCs (4.3%), and at six months in 2 RCCs (1.1%). The presence of patent artery one month after cryoablation was significantly associated with tumor enhancement at the same time point (P = 0.015). There was no association between patent arteries one month after cryoablation and treatment effectiveness (P = 0.693). Conclusion: Patent arteries in the ablated renal parenchyma are commonly observed on CT examination after percutaneous cryoablation of RCC. However, they gradually disappear and do not require specific treatment.